Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

Vaccine. 2008 Jul 23;26(31):3885-91. doi: 10.1016/j.vaccine.2008.05.012. Epub 2008 May 27.

Abstract

Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001.

Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA.

Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 microg/ml and at least 89% of infants had IgG >0.35 microg/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 microg/ml for more than 96% infants (>1.3 microg/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 microg/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%).

Conclusion: 7PCV and 23PPV are immunogenic in this population.

MeSH terms

  • Antibodies, Bacterial / blood
  • Australia
  • Bacterial Capsules / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Immunization Schedule*
  • Immunoglobulin G / blood
  • Infant
  • Longitudinal Studies
  • Meningococcal Vaccines / immunology*
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / immunology*

Substances

  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Antibodies, Bacterial
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Immunoglobulin G
  • Meningococcal Vaccines
  • Pneumococcal Vaccines